2140306-00-7
Chemical Structure
Prucalopride-13C,d3
- CAS No.: 2140306-00-7
- Formula:C1713CH23D3ClN3O3
- Molecular Weight:371.88
IUPAC Name: 4-amino-5-chloro-N-(1-(3-(methoxy-13C-d3)propyl)piperidin-4-yl)-2,3-dihydrobenzofuran-7-carboxamide
InChIKey: ZPMNHBXQOOVQJL-KQORAOOSSA-N
SMILES: [2H][13C]([2H])([2H])OCCCN(CC1)CCC1NC(C2=C3C(CCO3)=C(C(Cl)=C2)N)=O
Biological Activity: Prucalopride-13C,d3 is the 13C- and deuterium labeled Prucalopride[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Prucalopride-13C,d3 | 99.0% | Prucalopride-13C,d3 is the 13C- and deuterium labeled Prucalopride. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Prucalopride (Standard) | ≥98% | Prucalopride (Standard) is the analytical standard of Prucalopride. This product is intended for research and analytical applications. Prucalopride is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pKis of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Prucalopride | 99.93% | Prucalopride is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pKis of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||